UWELL BIOPHARMA INC.
Update：2025/07/25
Industries
Main Industry
Health Care
Main Product/Service
Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient.
Founded Year
2020
Unified Business No.
83304134
Status
Active
Number of Employees
23
Total Paid-in
Capital
167,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
UWELL BioPharma, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotheraputics designed to harness the power of a patient’s own immune system to target and eradicate cancer cells. We do this using our engineered autologous cell therapy, which we believe is a transformational approach to the treatment of cancer. Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. UWELL BioPharma is a cellular therapy company based in New Taipei City, Taiwan. UWELL has a strong management team and a team of professional and experienced scientists who are developing cutting edge technology to help fight cancer. Uwell Has a strong collaboration and close interaction with excellent clinical teams and partners in Taiwan and China, as well as in Malaysia. UWELL has generated and advanced a broad portfolio of product candidates to target hematological tumors.
